Treatment of morphoea with hydroxychloroquine results in a high response rate among patients, with a low rate of adverse effects, according to a recent study. However, prospective studies are warranted to establish its true efficacy.
A recent study suggests the use of Mohs micrographic surgery (MMS) for eyelid sebaceous carcinoma (SC) without orbital involvement to help prevent its recurrence. However, MMS has not succeeded in changing the long-term outcomes regarding metastasis or tumour-related mortality.
A lot of rosacea patients are obese and have longer exposure to sun, a study reports. Depending on rosacea severity, patients may also have neurological, psychiatric and gastrointestinal, or metabolic and cardiovascular system disorders.
Antinuclear antibody (ANA) negativity appears to increase the likelihood of developing malignancy in patients with adult-onset dermatomyositis (DM) within 3 years of diagnosis of their DM, according to a recent study.
New drug applications approved by US FDA as of 16 - 30 April 2019 which includes New Molecular Entities (NMEs) and new biologics. It
does not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
Treatment with 300-mg secukinumab confers benefits among patients with palmoplantar pustular psoriasis (PPP) in terms of Palmoplantar Psoriasis Area and Severity Index (PPPASI75) responses over 52 weeks and improved quality of life (QOL), results of the 2PRECISE study have shown.